In the expanded data set, Regeneron found 2.8% of patients who received REGN-COV2 had a medical visit related to COVID-19 through to Day 29, compared to 6.5% of people in the placebo cohort. The p-value was 0.024. Regeneron saw a bigger effect in patients with one or more risk factors, such as being over 50 years of age or having a body mass index greater than 30. In that high-risk subgroup, Regeneron linked REGN-COV2 to a 72% reduction in medical visits.
At day 29, the percentage of patients who were hospitalized with Covid-19 was 1.6% (5 of 309 patients) in the LY-CoV555 group and 6.3% (9 of 143 patients) in the placebo group (Table 3). The percentage of patients according to the LY-CoV555 dose who were hospitalized was similar to the overall percentage, with 1.0% (1 of 101) in the 700-mg subgroup, 1.9% (2 of 107) in the 2800-mg subgroup, and 2.0% (2 of 101) in the 7000-mg subgroup. In a post hoc analysis examining hospitalization among patients who were 65 years of age or older and among those with a BMI of 35 or more, the percentage who were hospitalized was 4% (4 of 95) in the LY-CoV555 group and 15% (7 of 48) in the placebo group. Only 1 patient in the trial (in the placebo group) was admitted to an intensive care unit.
셀트리온 total 54% 고위험군 68%
리제네론 total 67% 고위험군 72%
릴리 total 75% 고위험군 73%
이런 글이 있던데 결과적으로 셀트리온이 리제네론이나 릴리보다 나을게 없는거 아닌가요?
저는 주주도 아니고 관심있게 보고 있었는데
해석하는게 달라서 의문이 생기네요.
잘못된게 있으면 알려주시면 감사하겠습니다.